Abstract
The direct oral anticoagulant dabigatran (D) requires no routine therapeutic monitoring. Yet, drug interactions may increase its inherent bleeding risk, especially in the elderly. We aimed to evaluate to what extent co-prescription of P-gp antagonists with D may increase its plasma levels and lead to bleedings in usual conditions of care.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Proceedings for Annual Meeting of The Japanese Pharmacological Society
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
